That's what you call capitulation. very oversold. patience here will pay.
The aircraft will be delivered in stages, with 10 to be delivered in 2017, 25 in 2018 and 15 in 2019, the airline said in a Hong Kong Stock Exchange filing.
China Eastern said "the extent of the price concessions granted to the company under the purchase agreement is more favorable than price concessions" in a 2014 agreement, without giving further details.
BA recently traded at $143.00 within a 52-week trading range of $116.32 - $158.83.
Next dilemma please!
Buttttt Lagarde said IMF is ready to open up the checkbook again to Greece if they ask. Apparently Greece is holding out for some reason, hoping for better terms. This has got to go away even if only temporarily so we can move on! Ridiculous!!!
The gift that just keeps on giving!
The Industrial Select Sector SPDR Fund (XLI) tracks the industrial sector in the US (SPY). It rose 0.50% on July 1. Boeing (BA)—an industrial sector company—rose 1.45%. The SPDR Dow Jones Industrial Average ETF Trust (DIA) is another industrial sector gauging fund in the US. It rose 0.90%. XLI has yielded -3.98% YTD (year-to-date), while DIA stands at -0.27% YTD.
Is the bad news priced in? This hit over $100 in February and had dropped back down and done absolutely nothing since. What will it take? Management seems to think by adding a few pennies to the dividend it will keep investors interested. News flash "it ain't happening!"
....According to Zacks, “Gilead’s first-quarter earnings were above expectations as well as the year-ago figure. Total revenues climbed substantially over the prior year. We are impressed with Harvoni, which was up approximately 70% sequentially in the first quarter. We are pleased with the company’s dividend and share repurchase program, which should increase shareholder return. We are nevertheless concerned about additional pricing measures in the form of rebates and discounts which could lead to a slowdown in Harvoni sales in 2015. The anticipated continued decline in Atripla sales due to newer HIV therapies is also concerning. Meanwhile, several companies including AbbVie Inc. have launched their HCV treatments in the market.”
GILD has been the subject of a number of other recent research reports. Analysts at Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $127.24 price target on the stock in a research note on Wednesday. Analysts at Argus set a $150.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Analysts at Sanford C. Bernstein reiterated an “outperform” rating and set a $125.00 price target on shares of Gilead Sciences in a research note on Friday, May 29th. Analysts at Deutsche Bank reiterated a “buy” rating and set a $125.00 price target on shares of Gilead Sciences in a research note on Saturday, May 23rd. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Saturday, May 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $122.51.
I think the Greece downside has already played out. The vote will more than likely be yes and the europeans will once again restructure their debt. The PM will have to step down and then they'll have another election and a new gov't to deal with. Basically more of the same.
The only certainty in today's market is uncertainty. It's always something sayeth Gilda!